A new trading day began on Tuesday, with Phathom Pharmaceuticals Inc (NASDAQ: PHAT) stock price down -4.73% from the previous day of trading, before settling in for the closing price of $6.56. PHAT’s price has ranged from $6.07 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -37.62%. With a float of $34.90 million, this company’s outstanding shares have now reached $68.32 million.
Let’s determine the extent of company efficiency that accounts for 452 employees. In terms of profitability, gross margin is 85.02%, operating margin of -1096.02%, and the pretax margin is -1292.14%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 48.96%, while institutional ownership is 68.89%. The most recent insider transaction that took place on Jan 21 ’25, was worth 43,371. In this transaction CFO and CBO of this company sold 6,583 shares at a rate of $6.59, taking the stock ownership to the 93,546 shares. Before that another transaction happened on Jan 21 ’25, when Company’s Chief Operating Officer sold 7,886 for $6.59, making the entire transaction worth $51,957. This insider now owns 233,390 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.66% during the next five years compared to -137.06% drop over the previous five years of trading.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Here are Phathom Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.69, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -4.12 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Looking closely at Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days average volume was 0.96 million, which is a drop from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 30.33%. Additionally, its Average True Range was 0.54.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 0.52%, which indicates a significant decrease from 4.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.68% in the past 14 days, which was lower than the 89.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.04, while its 200-day Moving Average is $11.84. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $6.51. Second resistance stands at $6.76. The third major resistance level sits at $6.93. If the price goes on to break the first support level at $6.09, it is likely to go to the next support level at $5.92. Should the price break the second support level, the third support level stands at $5.67.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
With a market capitalization of 427.36 million, the company has a total of 68,377K Shares Outstanding. Currently, annual sales are 680 K while annual income is -201,590 K. The company’s previous quarter sales were 16,350 K while its latest quarter income was -85,580 K.
